International Stem Cell Corp. - Die alternative !

Hey biotech freaks,

Auf der suche nach einer günstigen Stem Cell Company mit alleinstellungsmerkmal und Break Even in 2012 ? Hier könnt ihr euch einlesen: "Connecting the dots ...... "

Last Friday's conference call by Ken Aldrich, chairman of the board of International Stem Cell Corp. (OTCBB:ISCO), was an extraordinary demonstration of this company's accelerating progress. Typically, however, this giant step will not be understood by most of the usual suspects. This is neither new, nor surprising. In fact, there's an upside that I'll explain later.

This alert will be longer than usual, but it is about a critical breakthrough I need to explain. On the morning of the conference call, ISCO issued a press release announcing it had cleared the final hurdle to opening and operating its own manufacturing facility in Oceanside, Calif. Aldrich himself played down the announcement, because it was not an amazing scientific breakthrough like ISCO's recent discovery that parthenogenic stem cells can be derived from immature unfertilized human ovum. Indeed, the oocyte discovery was a major scientific breakthrough and was covered in the important Genetic Engineering & Biotechnology News.

This, however, is a financial newsletter. The oocyte breakthrough made scientific news, but I want you to know why it is important to investors. In short, it simplifies and accelerates ISCO's grand strategy of building the bank of 50-100 immortal parthenogenic stem cell lines that will “immune match” nearly all of the world's population. The opening of ISCO's Oceanside manufacturing facility is a financial breakthrough at least as important. Inside the company, there is real excitement. Key people see the opening of state-of-the-art stem cell production facility as a “huge” deal.

One such person is Jeffrey Janus, with whom I spoke extensively about the new facility. Janus is both senior vice president of operations for ISCO and the president and CEO of Lifeline Cell Technology, which will provide expertise needed to run the facility. For new readers, let me explain that Lifeline is ISCO's wholly owned subsidiary. It already sells a wide array of human adult cell and stem cell-related products to researchers. Already, Lifeline was on track to provide the revenues to support ISCO's therapeutic research, perhaps as early as next year. This new facility, however, moves Lifeline and ISCO up into a higher orbit.

The reasons are somewhat complex -- probably too complex for typical financial writers and bloggers. As I said earlier, however, this is a good thing for my readers. Remember, Breakthrough Technology Alert is about long-run transformational profits. Unlike those obsessed with fluctuations, I don't want ISCO's stock price going through the roof until all my readers have had a chance to buy as much as they want.

And I do, by the way, still consider the company grossly underpriced. I’m not, however, going to keep issuing specific buy alerts – as you know I look at ISCO as a long-term transformational profit opportunity, of which we’re still at the beginning. With that said, I do hope that those who do not yet own sufficient ISCO equity are watching the stock and establishing a position over time and buying on any price pullbacks.

If uninformed writers manage to drive the stock price down in the short run, that serves our long-term purposes perfectly. The news that Ken Aldrich gave on Friday will, in fact, move the stock upward, but it will take time. Serious biotech analysts were paying attention to that call, and when they've done their due diligence, ISCO will be seen in a new light by important players.

What You Must Know About ISCO's New Facility

There are several important things to know about the Lifeline facility. One is simply that it puts ISCO into the rarefied category of stem cell companies that are not just R&D companies. To the best of my knowledge, there are only two other SC companies that have similar production abilities, Geron (GERN: NASDAQ) and BioTime (BTIM: AMEX). And you probably know what's happened to their valuations.

Another thing you must know about this facility is who runs it. These are not nameless lab technicians. They are renowned scientists and executives who have already made pharma history. I'll give you more on that after explaining the facility's central role in ISCO's long-term financial strategy.

In a word, this manufacturing facility is the backbone of ISCO's strategy to bring the company's unique SC technologies to profitable clinical uses. This facility provides ISCO with its own cGMP (current good manufacturing practice) environment. It will meet, therefore, the government's most stringent requirements for clinical-grade products. As a result, ISCO products will be eligible for clinical uses. Already, in fact, Janus tells me that both for-profit and academic researchers are committing to buying Lifeline's expanded products and services.

The bigger impact, however, will be on ISCO's own SC therapy pipeline. This is because R&D companies, which include most stem cells companies, have major disadvantages. One is, obviously, that they must contract with outside facilities to manufacture product. This, of course, raises costs. But the impact is much more profound. If you are an R&D company developing a biotech product, you will wait until you have developed your product to a certain point before hiring someone to develop large-scale manufacturing abilities.

Often, however, that process yields unexpected results. Companies often discover that their products don't scale up as expected. Then, of course, it's back to the drawing board to try again. This is not just expensive. It is time-consuming. Moreover, an R&D company that works with an outside manufacturing company has to expose its intellectual property to third parties. Sure, everybody signs nondisclosure and noncompete contracts. In the real world, however, R&D firm secrets have been passed on to others by individuals who work for third-party manufacturers.

Now that ISCO has its own cutting-edge manufacturing facilities, its time line has been drawn in significantly. Product development will take place in parallel with scaling and manufacturing. It will all be done in-house, far more cheaply and with far greater security.

Just as significantly, ISCO is now in a vastly enhanced position to help external collaborators and researchers. There is no other SC company that is so well positioned to take advantage of this capability. The reason is somewhat complicated, but important.

Intellectual Property -- Poised to Profit

As Aldrich explained during the conference call, a crucial part of the company's strategy is based on ISCO's complete ownership of the human parthenogenic stem cell (hpSC) platform. In this aspect, ISCO is completely unique. Most stem cell companies pay royalties to the Wisconsin Alumni Research Foundation or other holders of SC patents. ISCO needs neither licenses nor permission from anyone to pursue therapies. In fact, it is in position to license its parthenogenic platform technology to many other companies and academic researchers.

Now, this is where it gets really interesting. In the world of stem cell intellectual property (IP), patents are awarded based on cell types. Once these cell types are developed from embryonic or the virtually identical induced pluripotent stem cells, they will be patented. Anybody who wants to use them will pay royalties -- and, in some cases, most of their profits -- to the IP holders. Herein is the rub. Researchers believe parthenogenic stem cells will be able to do most, if not all, of what embryonic or induced pluripotent stem cells can do.

This means that any therapeutic use of embryonic or induced pluripotent stem cells discovered can be modified by ISCO to use parthenogenic stem cells, which it owns completely. As scientists discover new embryonic and iPS cell therapies, the odds are that someone, either inside or outside ISCO, will be able to backward engineer a parthenogenic alternative. Moreover, in many cases, immune-matched parthenogenic stem cells could have huge inherent advantages over other stem cell types, both medically and ethically.

As I mentioned earlier, important scientists outside ISCO are, in fact, working to perfect hpSC therapies now. ISCO will retain manufacturing rights to the products created by these collaborators. The new facility will not only accelerate hpSC therapy development, it assures that ISCO will get a bigger portion of profits from these therapies. But there are other benefits, as well.

As Janus says, “Since ISCO retains manufacturing rights from work done with its academic collaborators, we have the ability to monitor these collaborations and have the ability to transfer the technologies developed through academic institutions into a manufacturing environment quickly and efficiently. Moreover, ISCO can utilize its manufacturing team from its Lifeline subsidiary to assist collaborators.

“Lifeline is currently manufacturing human cells and media for the research market, and its staff is experienced in manufacturing cells in a cGMP environment. Therefore, with this facility, ISCO can conduct its therapeutic research and development and transfer technology developed through its many collaborations with academic institutions in parallel with oversight from scientists skilled in therapeutic cell and media manufacturing.”

Let me give you a few examples of the ways that this capability will pay off:

1. ISCO can obtain donated human oocytes from local fertility clinics and derive parthenogenic stem cell lines under regulatory approved standards. This results in the clinical-grade product needed as the company builds the first bank of immune-matched stem cells.

2. In 2009, ISCO announced therapeutic work with Dr. Paul H. Chen to use its laboratory-grown human corneal epithelial cells to improve healing in PRK laser eye surgery. Now ISCO is moving the manufacturing and automation of this technology into its clinical-grade manufacturing facility in Oceanside.

3. Dr. Hans Keirstead at the University of California at Irvine is using ISCO’s parthenogenetic stem cells to develop retinal tissue for the treatment of macular degeneration and retinitis pigmentosa. ISCO can now use its facility in concert with Keirstead’s group to transfer the technology into a clinical-grade manufacturing environment to produce cells for future clinical trials.

Who Is Lifeline?

As I said earlier, the people running this new facility are not just generic lab technicians. If you know anything about the human cell product industry, you know the word “Clonetics.” The Clonetics brand of normal human cell systems is the leading brand, with the largest market share of human cell products sold today.

The people who created and pioneered the formation of the Clonetics products, including the quality-control standards and the manufacturing systems, are now working for ISCO’s wholly owned Lifeline Cell Technology. This, for any intelligent observer, is a really big deal.

There is no more capable team, in both scientific and financial terms, in the human cell business.

Moreover, the history of the Clonetics team bears directly on ISCO's forthcoming cosmeceutical skin product. I've written a lot about this remarkable product and have personally watched it work on my wife. Even some of my male friends who've seen those results tell me they're going to buy and use the product when it comes to market.

Regardless, Clonetics Corp. was founded in the late 1980s to culture human skin cells to cure burn victims. The idea was to culture and expand the burn victims’ own cells (keratinocytes) and use them to help heal the burn victims' wounds. Interestingly, the team faced the same purity and contamination issues the stem cell industry faces.

In those days, keratinocytes were cultured using a technology utilizing feeder layers made of human fibroblast cells to provide nutrition to the skin cells being cultured. It also utilized bovine serum. This means that before the new cultured cells could be used to treat wounds, the contaminants had to be removed. The feeder layers and bovine serum had to be eliminated.

If you've read my discussions about Geron's IP, by the way, this will sound familiar to you. As you know, Geron holds the patent on a feeder-free medium for stem cell culturing.

Regardless, Clonetics managed to create a human keratinocyte growth system that eliminated feeder layers and serum. It did this, incidentally, with the help of Dr. Richard Ham of the University of Colorado at Boulder’s renowned Molecular, Cellular and Developmental Biology Department. This technology, in turn, contributed directly to the technology used in present stem cell growth systems that eliminates feeder layers and serum.

The Clonetics team, now at ISCO's Lifeline, was in some sense too far ahead of its time. No one at the FDA truly understood its breakthrough technology. Facing the all-too-typical regulatory roadblocks, it set aside its original goal of providing skin cells for burn victims. Instead, it turned to the research products market, which is far less regulated.

Clonetics created and sold human cell systems for many different cell types. It sold mammary and prostate cells and growth media for cancer research. It created and sold muscle cell systems, as well as systems for heart and blood vessel cells needed in cardiovascular disease research. Other scientists used these products to create many therapeutic applications that have since been approved by various countries' regulatory bureaucracies. The first wound healing products for skin replacement came from research using Clonetics products, as were products for heart repair.

Clonetics was eventually sold to BioWhittaker, which required, of course, that the key team stay with the company. BioWhittaker was later sold to Cambrex Corp. and eventually to Lonza Corp., which sells Clonetics products today. Many of the core Clonetics people were freed from their contracts and gravitated back together at Lifeline. Now Lifeline is opening a world-class facility with capabilities that I can't even tell you about, though I promise I will when this information can be shared.

The Clonetics/Lifeline team intends to repeat its earlier success making systems to grow human stem cells and superior culture media systems. I'm betting it'll do it. Already, it has proven its abilities with such important discoveries as the successful creation of cornea tissue.

Connecting the Dots

Now, think about this face product in perspective. I predicted in one of my very first issues that a simple stem cell-based cosmetic product would be one of two great breakthroughs for the regenerative medicine industry. Experienced colleagues and financial analysts at Agora Financial agree with me.

Cosmetic products are, I know, trivial in real human terms. As a species, we spend way too much time trying to look younger. There are much more important challenges and goals for regenerative medicine: serious medical conditions that can and will be cured by stem cell therapies.

On the other hand, the market for truly effective skin treatments is worth billions. If you listened to the conference call, you know that an awful lot of the follow-up questioning was about the cosmeceutical. There's enormous interest and chairman Aldrich has, in fact, been trying to damp down that enthusiasm.

He's not, in fact, happy that I'm writing about it now. He and his team are working on much bigger technologies. They're focused on perfecting cures for neural disease, liver disease, macular degeneration and diabetes, among others. This is a driven company full of dedicated people. Not only do they dislike the distractions that come from this frenzy over a product that caters primarily to vanity, I sense that they are a little embarrassed to find themselves participants in an industry that is known for vague promises made by celebrity spokesmodels.

On the other hand, it would be irresponsible for me not to tell you what I can. Most importantly, I think that this product could provide significant revenues to support ISCO's far more important work. And I have to admit, I have enjoyed watching my wife look younger.

The Lifeline team is improving the product further both in terms of its effectiveness and its stability. So please don't call ISCO for more information about the cosmeceutical. I've already irritated the company enough. I promise you that I will get you any public information as soon as it's available. Aldrich said during the conference call that he was on track to making major decisions regarding the product in 60 days.

This, however, is what we know now. The base of the skin care product is Lifeline’s keratinocyte medium, specifically designed to grow skin cells in the laboratory. It is combined with extracts from stem cells. The people who have developed this product are the world-class scientists of the Clonetics/Lifeline team. And now they have the cGMP facility to improve, test and manufacture it. Janus tells me that nanotechnology will play an important role in the final version of the cosmeceutical.

All that, reading between the lines, is the huge breakthrough announcement I expected. I didn't expect chairman Ken Aldrich to connect all the dots last Friday with trumpets playing a fanfare in the background. And he didn't. As I said earlier, though, I'm glad he didn't. All the information was there, however, for those who understand the implications. Now I hope you do.

I hope you understand, as well, both the long-term potential of this company and the short- to medium-run revenue streams that will keep the company healthy until it achieves its ultimate potential.

One other important bit of news was Aldrich's mention that he is considering a move from bulletin board status to a major stock exchange listing. This is exactly what BioTime has done, and it has allowed institutional investors to finally buy into that company. Many of those same analysts are watching ISCO now.

At some point, the broader media and market are going to catch on to what's going on at ISCO and your opportunity to buy at ground-floor prices will be gone forever ....

MFG
Chali  

International Stem Cell's Research Scientists Successfully Completed the First Series of Preclinical Animal Trials of Neurona...
print
Intl Stem Cell Corp (OTCBB:ISCO)
1 Month : September 2011 to October 2011

International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.

Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The results of these safety and survival studies is a very important step along the path towards the clinical use of such cells."

Although most cases of Parkinson’s disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component “autologous” treatment, that is to say treatment using the patient’s own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson’s disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.

ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.

Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com .

MFG
Chali  

US85857B1008?
hat dieser Wert etwas damit zu tun?

Gru$$  

ISCO to Expand Cosmeceutical Product Lines

One, ISCO has been perfecting the process of growing and preserving the active ingredient in parthenogenic stem cells used for their cosmeceutical skin care product line. As a result, they've been able to stockpile enough of the growth factors found in stem cells to allow additional marketing efforts. In the past, availability of product has limited those efforts.

Moreover, the company has announced development of several new skin care products, including one designed to work on the sunken area under the eyes. The skin care line, while not cosmically meaningful, is doing very well for the company and is on track to fund serious work, such as ISCO's liver cell science.

Also, ISCO has brought in an experienced corporate executive to help move the company forward. Dr. Andrey Semechkin, currently CEO, will become co-chairman. Kurt May, currently senior vice president, will take the helm as president and CEO.

From the press release:
"Prior to joining ISCO, Mr. May was a senior executive with GTE Corp. and with PriceSmart Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and assistant dean of UCSD's Rady School of Management from 2005-09.

"During his tenure as PriceSmart's chief operating officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability and expanding staff from 356 to more than 4,200.

"'In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success,' said Kenneth Aldrich, co-founder and co-chairman of ISCO."

MFG
Chali  

ist  http://www.ariva.de/US85857B1008
#eine Tochter oder hat dieser Wert mit dem Unternehmen nichts zu tun?

Gru$$  

Nein,diese Stem Cell Innovation ist doch dieser "Brunneta-Schrott" aus den Pinks,hat mit ISCO.ob rein garnichts zu tun !

MFG
Chali  

von dir !
ich halte selbst noch 20 Millionen Aktien!

Danke

Gru$$  

 

The first company is International Stem Cell Corporation (ISCO.OB). ISCO uses a technique called parthenogenesis, which creates stem cells from unfertilized oocytes. What is interesting and intriguing about ISCO is the strategy it is using. Instead of going after a disease and clinical trials procedure first, ISCO instead is focused on cosmetics, namely a day and night skin cream combo where stem cells are an active ingredient to rejuvenate skin cells. FDA approval is not required for this product and is already on the market in a limited basis.

On the company’s last quarterly conference call it expected to sell a thousand bottles in a limited launch. Instead, the company sold seven thousand bottles. That is the good news. The bad news is that ISCO cannot sell the product again until sometime in the third quarter as it underestimated demand and the cells needed for the product take two to three months to grow. Now that ISCO knows more about the demand to expect for the product, there should hopefully be no more gaps in product production and could turn profitable within the next three to five quarters in my opinion. With a profitable cosmetic line the company then plans to fund therapeutic research and future clinical trials for liver diseases, Parkinson’s and eye diseases.

MFG
Chali

P.S. Good News travels slowly ......  

Von Ihnen kommen bereits 7 der letzten 20 (oder weniger) positiven Bewertungen für Chalifmann3.

 

CARLSBAD, Calif.--(BUSINESS WIRE)-- International Stem Cell Corporation (OTCBB:ISCO.OB - News) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline’s products in Australia and New Zealand under Lifeline’s own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company’s website www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

“I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report,” said Dr. Keller. “Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they’ve seen are amazing.”

Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: “Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

“In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand.”

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin’s own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use

MFG
Chali  

CARLSBAD, Calif.--(BUSINESS WIRE)-- International Stem Cell Corporation (ISCO) (OTCBB:ISCO.OB - News) today announced financial results for the three-month and nine-month periods ended September 30, 2011. ISCO is a development-stage biotechnology company that created, patented and is commercializing a powerful new stem cell technology called parthenogenesis which promises to advance significantly the field of regenerative medicine.

ISCO reported revenue of $0.84 million for the quarter ended September 30, 2011, a 141% increase from the same period of the prior year. For the nine months ended September 30, 2011, the Company reported revenue of $3.47 million, a year-over-year increase of 227%. The increases in revenue was driven by strong sales from the initial launch of ISCO’s wholly-owned subsidiary Lifeline Skin Care (LSC), which commenced operations in the fourth quarter of 2010. In addition, steady growth in sales from ISCO’s other wholly-owned subsidiary, Lifeline Cell Technology (LCT), contributed to the increases in revenues for both periods.

The Company continued to invest in the development of new technologies, products and channels of distribution. For the three months ended September 30, 2011, development expenses, excluding cost of sales, were $3.60 million, an increase of 15% compared to the third quarter of 2010, reflecting increased R&D activities on therapeutic programs and new product development for both subsidiaries. Sales and marketing expenses related to our skin care products, partially offset by a reduction in general and administration expenses, also contributed to the increase in development expenses.

For the nine months ended September 30, 2011, development expenses, excluding cost of sales, were $10.77 million, an increase of 30% when compared with the prior year period. The increase is attributed primarily to increased research activities on therapeutic products and product development programs for LSC and LCT, increased stock-based compensation expense, increased headcount and higher general corporate expenses coupled with increased sales and marketing expenses related to our skin care products.

Dr. Andrey Semechkin, co-Chairman and CEO, commented, “We are pleased with the rapid growth in sales of our two subsidiaries, LSC and LCT. Together, these business units are providing much-needed capital to help support our growth as well as the research leading to the development of new stem cell technologies and products.” Kurt May, President and COO, noted, “Our focus continues to be on maximizing the performance of our operating subsidiaries, advancing the development and commercialization of our therapeutic products and strengthening our organization and operating systems to accommodate our anticipated rapid and significant growth.”

Third Quarter 2011 Highlights:

Important developments and milestones for International Stem Cell in the third quarter included:

-- Continuing to solidify its leadership team with the addition of Linh Nguyen as ISCO’s new Chief Financial Officer. Further, the Board of Directors elevated Kurt May to President and Chief Operating Officer and Dr. Semechkin to co-Chairman of the Board and Chief Executive Officer.

-- Renewing the marketing agreement with John Mauldin to promote its Lifeline Skin Care products and commenced a new sales channel to resorts and destination spas.

-- Lifeline Cell Technology began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia.

-- ISCO scientists successfully completed the first series of preclinical studies designed to support the application of neuronal cells derived from hpSCs. These experiments were designed to demonstrate that the derived neuronal cells were able to survive in mouse brains without giving rise to tumors.

MFG
Chali  

 

Patrick Cox in"Breakthrough Technology Alert" (wurd bereits anfang november publiziert):

There is an area of "trading" that does work. It is taking advantage of dips in great companies to acquire stock and then selling some when the price spikes up again.

The only way this works is if you know something the market doesn't. And the market doesn't know jack about science. This means that there are a number of companies whose science nearly predestines them to become legends -- unless some other, even more amazing technology leapfrogs them. I consider, for example, Galectin Therapeutics, Arrowhead (NASDAQ: ARWR), NanoViricides (OTCBB: NNVC), BioTime (AMEX: BTX), International Stem Cell (OTCBB: ISCO), Aura Systems (OTCBB: AUSI) and Star Scientific (NASDAQ: CIGX) to be firmly part of this group.  

wenn ich schon dabei bin hier was vom mai 11

 

International Stem Cell’s Lifeline Cell Technology Subsidiary Expands Sales & Distribution While Enhancing Manufacturing Ca...
Date : 06/29/2011 @ 8:00AM
Source : Business Wire
Stock : International Stem Cell Corporation (ISCO)

International Stem Cell’s Lifeline Cell Technology Subsidiary Expands Sales & Distribution While Enhancing Manufacturing Ca...

International Stem Cell Corporation Common Stock (OTCBB:ISCO)
Intraday Stock Chart
Today : Wednesday 29 June 2011
International Stem Cell Corporation (OTCBB:ISCO) (www.intlstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells derived from unfertilized human eggs, reports that its wholly owned subsidiary, Lifeline Cell Technology (Lifeline), grew 2011 first quarter product sales by 35% and gained well over 200 new customers compared with the prior year through new product introductions and the development of worldwide distribution channels. Lifeline also made significant progress in its strategy to expand its product applications into manufacturing human tissues and cells for clinical use. Lifeline Cell Technology develops, manufactures and markets the Lifeline® brand of cell culture products used by researchers to grow human cells for basic and pre-clinical research. Lifeline also fulfills an important role in parent ISCO’s long-term strategy to be a leading developer and manufacturer of human cells and human-cell-based products for clinical applications.

Lifeline’s chief executive officer, Jeffrey Janus, stated, “Our product sales growth was largely due to the development and launch of more than 30 new products in 2010, including products that allow researchers to study human stem cells. Lifeline also opened new distribution channels in Japan, India, Taiwan, South Korea and Singapore and has achieved significant sales in those new markets. Importantly, we have also moved closer to validating the feasibility of ISCO’s strategic plan as our proprietary FibroLife® media is being used to cultivate tissue-engineered blood vessels for Cytograft Tissue Engineering in Novato, California. Cytograft’s vessels are expected to be used as coronary grafts for coronary bypass procedures, as peripheral grafts to prevent lower limb amputations and as living tissue shunts for hemodialysis patients.”

Cytograft’s technology was recently featured at the American Heart Association’s conference of emerging technology and can be viewed on the AHA’s “Emerging Science Series Webinar” at scientificsessions.org/emergingscience.

Cytograft’s chief executive officer, Todd McAllister, Ph.D., said, “Cytograft’s clinical programs are going forward in Phase III trials and we are excited to be working with Lifeline as one of our key media developers and suppliers as we transition to commercialization and as we develop our next generation platform.”

In anticipation of producing clinical grade products, Lifeline recently moved into new laboratory facilities that are capable of cGMP level manufacturing. Said Janus, “Lifeline Cell Technology provides ISCO the capacity to develop and manufacture human cell-based products for growing field of regenerative medicine, while at the same time generating revenue in the research market. The Cytograft opportunity is but one example of many potential clinical applications for Lifeline’s products.”

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.  

 

 

http://www.youtube.com/watch?v=CcXPMHqENys  

Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding
Date : 09/29/2011 @ 8:00AM
Source : Business Wire
Stock : International Stem Cell Corporation (ISCO)

Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding
print
Intl Stem Cell Corp (OTCBB:ISCO)
Intraday Stock Chart
Today : Thursday 29 September 2011
International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California’s 50th congressional district, which includes portions of San Diego’s North County.

Following the meeting, Rep. Bilbray stated, “I have tremendous respect for the innovative healthcare companies in my district, such as International Stem Cell, that are at the forefront of developing important new treatments and therapies. I’m committed to helping remove unnecessary regulations and barriers that may inhibit the research of new life science technologies, and I greatly appreciate the efforts of ISCO’s management team to clarify many of the issues surrounding their work.”

Said Dr. Semechkin, “We are very pleased to have the opportunity to meet with Congressman Bilbray and explain the importance of our parthenogenesis technology and how it differs from human embryonic stem cell development, particularly from an ethical standpoint. We look forward to continued discussions with Congressman Bilbray and his colleagues regarding the Dickey-Wicker Amendment. We believe that with increased understanding of our technology the National Institutes of Health (NIH) will support parthenogenesis research and development.”

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.  

Third Quarter 2011 Highlights:

Important developments and milestones for International Stem Cell in the third quarter included:

-- Continuing to solidify its leadership team with the addition of Linh Nguyen as ISCO’s new Chief Financial Officer. Further, the Board of Directors elevated Kurt May to President and Chief Operating Officer and Dr. Semechkin to co-Chairman of the Board and Chief Executive Officer.

-- Renewing the marketing agreement with John Mauldin to promote its Lifeline Skin Care products and commenced a new sales channel to resorts and destination spas.

-- Lifeline Cell Technology began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia.

-- ISCO scientists successfully completed the first series of preclinical studies designed to support the application of neuronal cells derived from hpSCs. These experiments were designed to demonstrate that the derived neuronal cells were able to survive in mouse brains without giving rise to tumors.  

 

sorry, höre schon auf damit, den ganzen rest an info gibts ein andermal...übrigens, schönes kaufsignal @0.62 liegt gegenwärtig vor (siehe chart)

International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care
Intl Stem Cell Corp (OTCBB:ISCO)

International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline’s products in Australia and New Zealand under Lifeline’s own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company’s website www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

“I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report,” said Dr. Keller. “Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they’ve seen are amazing.”

Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: “Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

“In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand.”

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin’s own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.  

Besten Dank für deine tolle Arbeit und das geniale Video über international Stem Cells,eigentlich hatte ich meinen einstieg auf 2013 verschoben,aber jetzt will ich doch schon 2012 dabei sein,hm ?

MFG
Chali  

Chali, sofern du nachstehende mitteilung noch nicht kennst, hilfts dir vielleicht für zeitpunktsfindung/einstieg ...solltest du eine ultralonge ISCO posi aufbauen wollen.

ich persönlich bewerte pipeline, produkte, management, perspektiven, background und potential von ISCO sehr hochwertig.
...bin aber befangen, habe bei 0.58 bereits eine position eröffnet (ist vorerst als längerer swing angelegt, schließe nicht aus, das die posi im depot stehenbleibt...time will tell)

wie bemerkt, ist nicht brandaktuell, hab´die pressnote von IR-dept. bereits anfang okt. per mail erhalten (weiß gar nicht ob die sonst noch wo publiziert wurde).


Subject:
International Stem Cell Subsidiary Commences New Skin Care Marketing Campaign

International Stem Cell Corporation (OTCBB:ISCO) today announced that its wholly owned subsidiary, Lifeline Skin Care, has launched a new marketing program. New promotional efforts include (1) rebranding the line to feature Lifeline's unique selling proposition; (2) creating greater consumer awareness through public relations as well as online marketing; and (3) re-marketing to existing users to strengthen brand loyalty. Research has established that the brand's proprietary stem cell technology is a critical point of difference in the skincare market, and it's also the reason to believe in the brand. New marketing materials feature the headline, "Someday, stem cells will change the world. Today, stem cells will change your skin." This messaging is now being communicated through online and traditional marketing and sales promotion materials.

The current marketing program follows six months in which little or no marketing was done by the company because initial sales that were booked in January from a December 2010 launch had far exceeded expectations and, as a result, also exceeded supplies of the unique stem cell extract that is the key ingredient in the Lifeline Skin Care products. The company has now built a substantial reserve inventory of the essential stem cell extract and has also designed new marketing programs to both minimize sudden surges in demand and permit controlled testing of new products and sales initiatives. The company has also re-engineered its quality control, logistics and customer service to deliver higher quality products and services to the consumer.

"Sales for the first two weeks of the new program were approximately 1,000 units, which is in line with our expectations and does not include any sales from pending initiatives to spas and medical clinics or international sales," said Donna Queen, Vice President of Marketing and Business Development.

"In keeping with the reporting practices of its parent company, International Stem Cell Corporation, revenue data will not be released except on a quarterly basis, but Lifeline Skin Care will continue to advise its customers and ISCO investors of new sales initiatives as a way of increasing customer awareness and referral business," said Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care. As previously announced, International Stem Cell Corporation defers all revenues associated with Lifeline Skin Care products until the 30 day right of return guarantee expires.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc
Donna Queen, Vice President
760-940-6383
dqueen@lifelineskincare.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com